KP-1461

Koronis has completed Phase 1a and b clinical studies of KP-1461. The Company has suspended a Phase 2 clinical trial of KP-1461. Koronis is currently conducting in vitro evaluation studies and evaluating results from the Phase 2 trial. At this time, there are no clinical trials currently open for enrollment.

Phase 2a Trial: Suspended

An Open-label, Multicenter, Mechanism Validation Study to Evaluate the Safety, Efficacy, and Tolerability of KP-1461 as Monotherapy for 124 Days in ARV-experiences, HIV-1-infected Subjects.

Phase 1b Trial: Enrollment Complete

A Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of KP-1461 in HIV+ Adults Who Have Failed Two or More Highly Active Antiretroviral Regimens (HAART).

Phase 1a Trial: Enrollment Complete

A Double Blind, Placebo Controlled Dose Escalation Study of the Safety Tolerability, and Pharmacokinetics of a Single Oral Dose of KP-1461 in Normal Healthy Adults

Patients or physicians who would like more information about current clinical trials should contact Koronis